Business Context and Reporting Period
Company: Kewaunee Scientific Corporation
Filing Type: Form 10-K (Annual Report)
Period Ended: April 30, 2008
Business Overview: The Company designs, manufactures, and installs laboratory and technical furniture, including cabinetry, fume hoods, and workstations. Products are sold primarily to pharmaceutical, biotechnology, educational, and healthcare sectors through dealers, a national distributor (VWR International, LLC), and competitive bids. Operations are segmented into Domestic and International divisions.
Key Financial Metrics
| Metric ($ in thousands) | Fiscal 2008 | Fiscal 2007 |
|---|---|---|
| Net Sales | $89,510 | $81,441 |
| Gross Profit | $19,172 | $15,086 |
| Gross Margin | 21.4% | 18.5% |
| Operating Earnings | $5,613 | $3,358 |
| Net Earnings | $3,134 | $1,540 |
| Diluted EPS | $1.23 | $0.62 |
| Operating Cash Flow | $3,391 | $8,635 |
| Total Assets | $50,606 | $45,240 |
| Working Capital | $15,920 | $12,331 |
| Short-term Borrowings | $4,551 | $3,489 |
| Long-term Debt | $5,027 | $4,325 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 10% to $89.5 million, driven by an 11% increase in Domestic Operations ($73.8 million) and a 6% increase in International Operations ($15.8 million).
- Margin Expansion: Gross profit margin improved to 21.4% from 18.5%, attributed to manufacturing efficiencies, lean techniques, and lower-cost global supply sources.
- Profitability: Net earnings more than doubled to $3.1 million ($1.23 diluted EPS) compared to $1.5 million ($0.62 diluted EPS) in the prior year.
- Order Backlog: Backlog increased to $58.7 million from $51.1 million, with over 80% expected to ship in fiscal 2009.
- Interest Expense: Decreased to $294,000 from $670,000 due to lower levels of bank borrowings.
- Dividends: The quarterly cash dividend was increased to $0.08 per share in May 2008, up from $0.07 per share in fiscal 2008.
Outlook, Risks, and Management Commentary
- Outlook: Management expects fiscal year 2009 to be profitable. Capital expenditures are anticipated to be approximately $2.0 million, funded primarily by operating cash flow.
- Raw Material Costs: Prices for steel, epoxy resin, and energy increased significantly in fiscal 2008. The Company bears the burden of cost increases between quotation and delivery due to firm-price quoting practices. Future profitability depends on the ability to pass these costs to customers.
- Customer Concentration: Sales to VWR International, LLC represented 13% of total sales in fiscal 2008. Loss of this customer would have a material adverse effect.
- Market Risks: The business is subject to volatility in the laboratory construction industry. Delays in construction projects can delay revenue recognition. International operations face risks related to currency fluctuations and local regulations.
- Liquidity: The Company has a $12 million unsecured revolving credit facility maturing in September 2010, with $4.6 million outstanding as of April 30, 2008.
Investor Verification Checklist
- Raw Material Hedging: Verify the Company's specific strategies for mitigating steel and resin price volatility, given the firm-price quoting model.
- Backlog Conversion: Monitor the conversion rate of the $58.7 million backlog into revenue in fiscal 2009, considering potential construction delays.
- Customer Concentration: Assess the stability of the relationship with VWR International, LLC, which accounts for 13% of sales.
- Debt Covenants: Confirm continued compliance with financial covenants (debt-to-net worth, fixed charge coverage) under the $12 million credit facility.
- International Growth: Evaluate the performance of the International segment (17.6% of sales) and exposure to foreign exchange rates.